Issues, Insights, and Expert Commentary on Comprehensive Care at Your Hemophilia Treatment Center

Click the “Start Program” button to indicate you have reviewed the CME/CE information for this activity.
Start Program


Release Date: February 10, 2017
Expiration Date: February 10, 2018
Estimated Time to Complete Activity: 1.25 hours
Minimum System Requirements:
  • Internet Explorer 7 (or higher)
  • Mozilla Firefox 4 (or higher)
  • Google Chrome (latest version)
  • Adobe Acrobat 6.0 (or higher)
  • Screen resolution 1024 x 768
Click here to contact Postgraduate Institute for Medicine (PIM)
Target Audience
This activity has been designed to meet the educational needs of hematologists, physicians, physician assistants, nurse practitioners, advanced practice registered nurses, registered nurses, physical therapists, social workers, and other specialists of the hemophilia treatment center (HTC) team, as well as other healthcare providers interested in the comprehensive care of patients with congenital or acquired hemophilia

Statement of Need/Program Overview
Hemophilia is the most common, severe, inherited bleeding disorder recognized in humans and makes up the largest proportion of patients followed in most bleeding disorders’ clinics and hemophilia treatment centers (HTCs).

Many of the clinicians who practice at HTCs, as well as at other types of hemophilia practices, are not able to regularly attend the major national and international society meetings, where they can view scientific posters and interact with the author(s) and/or expert(s) who provide perspective and insight about a range of clinical challenges and patient management issues frequently encountered in the HTC setting.

With the CME/CE NetWorkShops™ series, however, these meetings can be brought to busy clinicians in the form of webcasts and organized group workshops at or near HTCs. Healthcare professionals are now able to view, analyze, and discuss key meeting findings with recognized hemophilia experts while gaining ideas on how to apply new learning to their own clinical practice.

Educational Objectives
After participating in this activity, participants should be better able to:
  • Review clinical data about the comprehensive care of PWH
  • Review developments in hemophilia treatment, including newer factor concentrates, prophylactic strategies, and gene therapy.
  • Assess the efficacy of novel therapeutic agents when treating PWH with target joints
  • Implement individualized hemophilia management strategies which optimize adherence, outcomes, and utilization resources

Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hours

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to receive credit
A statement of credit will be issued upon receipt of a completed activity evaluation form and application for credit. Certificates can be printed upon completion.

PIM Contact Information
For information about the accreditation of this program, please contact Postgraduate Institute for Medicine at 1.800.423.3576

Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.

Planning Committee and Presenting Faculty
Chairperson:
Amy D. Shapiro, MD
Adjunct Professor, Pediatrics
Michigan State University
East Lansing Michigan
Medical Director & Pediatric Hematologist
Indiana Hemophilia & Thrombosis Center
Indianapolis, Indiana

Faculty:
Miguel A. Escobar, MD
Professor of Medicine & Pediatrics
Division of Hematology
University of Texas Health Science Center
Director
Gulf States Hemophilia & Thrombophilia Center
Houston, Texas

Steven W. Pipe, MD
Professor of Pediatrics and Pathology
Director, Division of Pediatric Hematology and Oncology
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, Michigan

Craig Kessler, MD, MACP
Professor of Medicine and Pathology
Chief of the Division of Coagulation
Director of the Coagulation Laboratory
Georgetown University Medical Center
Washington, DC

Robert Sidonio, Jr, MD
Clinical Director, Hemostasis/Thrombosis
Children's Healthcare of Atlanta
Assistant Professor, Pediatrics
Emory University School of Medicine
Atlanta, Georgia

Thomas Loew, MD
Division Director
Professor of Clinical Child Health
University of Missouri Health System
Columbia, Missouri

Clifford Takemoto, MD
Associate Director
Johns Hopkins University
Hemophilia Treatment Center
Associate Professor, Pediatric Hematology
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Ellis Neufeld MD
Associate Chief, Division of Hematology/Oncology; Medical Director
Boston Hemophilia Center
Egan Family Foundation Professor of Transitional Medicine in Pediatrics
Harvard Medical School
Boston, Massachusetts

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty Presenter/Planning Committee Reported Financial Relationship
Miguel A. Escobar, MD Consulting/Independent Contractor: Baxalta (now Shire), Novo Nordisk, Pfizer, Roche/Genentech, CSL Behring
Craig Kessler, MD, MACP Research Support: Baxter, Bayer, Biogen, Grifols, Novo Nordisk, Octapharma, Roche/Genentech Consultant: Baxter, Bayer, Biogen, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche/Genentech Scientific Advisory Board: Baxter, Bayer, Biogen, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche/Genentech DSMB: Dimension, Revo, NHLBI
Thomas Loew, MD No real or apparent conflicts of interest to report
Ellis Neufeld, MD Consulting Fees: Pfizer, CSL Behring, Baxalta, Novo Nordisk, Biogen IdecContracted Research (Institution): Novo Nordisk, Baxalta, Octapharma Other: DSMB — Bayer, Pfizer
Steven W. Pipe, MD Consulting Fees: Baxalta, Biogen Idec, CSL Behring, Novo Nordisk, Pfizer
Amy D. Shapiro, MD Consultant: Biogen IDEC, ProMedic Life Sciences, Kedrion BioPharma. Advisory Boards: Baxalta, Novo Nordisk, Biogen IDEC, Genentech. National Hemophilia FoundationClinical Research: Bayer Healthcare, Baxalta,, Biogen IDEC, CSL Behring, Daiichi Sankyo, Kedrion Biopharma,Novartis Pharmaceuticals, Novo Nordisk, OctoPharma, OPKO, ProMetic Life Sciences, PTC Therapeutics, Selexys

Note: All honoraria and income are paid to the Indiana Hemophilia & Thrombosis Center. Dr. Shapiro has no financial interest in any of the above listed companies.
Robert Sidonio, Jr.,MD Advisory Boards: Biogen, Baxalta, CSL Behring, Pfizer and Emergent Solutions
Clifford Takemoto, MD Grant Support: Novo Nordisk, Mast Therapeutics

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP Have no real or apparent conflicts of interest to report. Have no real or apparent conflicts of interest to report.
ECM: Patrick J. Crowley, MBA, President; Jodi Andrews, BS, Vice President, Operations; Jo-Ann Angelucci, BA, Program Director; Kathleen Krafton, BA, Medical Writer Have no real or apparent conflicts of interest to report.


Disclosure of Unlabled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM and Educational Concepts in Medicine do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Suport
This activity is supported by an educational grant from Novo Nordisk.